Mer­ck is eye­ing new im­munol­o­gy deals, chief med­ical of­fi­cer says: #JPM24

Mer­ck wants to beef up its im­munol­o­gy pipeline through ad­di­tion­al deals, the Big Phar­ma’s chief med­ical of­fi­cer Eli­av Barr said at an End­points News event on Tues­day.

“We’ll be look­ing for those im­munol­o­gy op­por­tu­ni­ties that we think can com­ple­ment or add a new facet to things,” Barr said.

The big phar­ma, which hous­es the best-sell­ing can­cer med­i­cine Keytru­da, has in­vest­ed sub­stan­tial­ly in im­munol­o­gy in re­cent years, in­clud­ing a $10.8 bil­lion buy­out of Prometheus last year. That deal gave Mer­ck an ex­per­i­men­tal treat­ment for in­flam­ma­to­ry bow­el dis­eases and firm­ly moved the com­pa­ny in­to the im­munol­o­gy field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER